Smith & Nephew (LON:SN) Price Target Increased to GBX 1,695 by Analysts at Goldman Sachs Group
Smith & Nephew (LON:SN) had its target price upped by Goldman Sachs Group from GBX 1,685 ($22.02) to GBX 1,695 ($22.15) in a research report sent to investors on Wednesday morning, ThisIsMoney.Co.Uk reports. The brokerage currently has a neutral rating on the stock.
Several other brokerages have also recently issued reports on SN. Berenberg Bank dropped their price objective on Smith & Nephew to GBX 2,185 ($28.55) and set a buy rating on the stock in a research note on Friday, November 1st. UBS Group reaffirmed a neutral rating and set a GBX 1,800 ($23.52) target price (down previously from GBX 1,830 ($23.91)) on shares of Smith & Nephew in a research report on Monday, October 28th. Credit Suisse Group dropped their target price on Smith & Nephew from GBX 1,770 ($23.13) to GBX 1,725 ($22.54) and set a neutral rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on Smith & Nephew from GBX 1,814 ($23.70) to GBX 1,711 ($22.36) and set a neutral rating on the stock in a research report on Monday, November 4th. Finally, Shore Capital reaffirmed a sell rating on shares of Smith & Nephew in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. Smith & Nephew presently has an average rating of Hold and an average price target of GBX 1,710.38 ($22.35).
LON:SN traded down GBX 1 ($0.01) during midday trading on Wednesday, hitting GBX 1,654.50 ($21.62). The stock had a trading volume of 1,617,521 shares, compared to its average volume of 3,250,000. Smith & Nephew has a one year low of GBX 1,376 ($17.98) and a one year high of GBX 1,998.40 ($26.11). The company has a market capitalization of $14.54 billion and a price-to-earnings ratio of 20.76. The stock has a 50-day moving average of GBX 1,777.34 and a 200 day moving average of GBX 1,770.72. The company has a quick ratio of 0.96, a current ratio of 2.00 and a debt-to-equity ratio of 44.00.
About Smith & Nephew
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Read More: What Factors Can Affect Return on Equity?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.